Symposium on renal lithiasis. Urinary tract infection and renal lithiasis.
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy / Q000378:metabolism; D002228:Carbenicillin / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D002701:Chloramphenicol / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D007668:Kidney / Q000503:physiopathology; D007669:Kidney Calculi / Q000188:drug therapy / Q000209:etiology*; D008709:Methenamine / Q000627:therapeutic use; D009268:Nalidixic Acid / Q000627:therapeutic use; D009582:Nitrofurantoin / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D014551:Urinary Tract / Q000473:pathology; D014552:Urinary Tract Infections / Q000150:complications* / Q000378:metabolism
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D011113:Polymyxins; D013449:Sulfonamides; D009268:Nalidixic Acid; D007612:Kanamycin; D002701:Chloramphenicol; D009582:Nitrofurantoin; D014295:Trimethoprim; D013752:Tetracycline; D002228:Carbenicillin; D008709:Methenamine; D013420:Sulfamethoxazole; D013307:Streptomycin